Sulfonylurea toxicity: Difference between revisions
m (Rossdonaldson1 moved page Sulfonylurea Toxicity to Sulfonylurea toxicity) |
No edit summary |
||
| Line 1: | Line 1: | ||
== | ==Background== | ||
==Clinical Features== | |||
==Differential Diagnosis== | |||
==Diagnosis== | |||
==Management== | |||
{{Sulfonylurea Toxicity}} | {{Sulfonylurea Toxicity}} | ||
== | ==Disposition== | ||
==See Also== | |||
*[[Hypoglycemia]] | |||
==External Links== | |||
==References== | |||
<references/> | <references/> | ||
[[Category:Toxicology]][[Category:Endocrinology]] | [[Category:Toxicology]][[Category:Endocrinology]] | ||
Revision as of 07:52, 9 June 2016
Background
Clinical Features
Differential Diagnosis
Diagnosis
Management
Hypoglycemia from Sulfonylureas[1][2]
Activated charcoal[3]
- Administer activated charcoal, preferably within 1 hr of ingestion
- Multiple doses may be beneficial, especially for glipizide
Glucose Treatment
- Initial therapy regardless of known cause
- Adults
- 50mL D50W bolus
- Start a D10 1/2NS drip (100mL/hr)
- Children
- 1mL/kg of D50W OR
- 2mL/kg D25W OR 5-10mL/kg D10W
- Neonate: 5-10 mL/kg D10W
Octreotide[4]
- Theoretical benefit to reduce risk of recurrent hypoglycemia
- Hyperpolarization of the beta cell results in inhibition of Ca influx and prevents insulin release
- 50-100 mcg subcutaneous in adults with repeat dosing Q6hrs
- 2 mcg/kg (max 150mcg) subcutaneously Q6hrs should be used in children
- Continuous infusion of 50-125 mcg/hr is an alternative in adults
- Administer octreotide for 24 hours, then after discontinuing, monitor for hypoglycemia for another 24 hours
Special Considerations
- Glucagon 5mg IM may be used as temporizing measure, e.g. while obtaining IV access
Disposition
See Also
External Links
References
- ↑ Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin N Am 2007; 25:347-356
- ↑ Howland MA. Antidotes in Depth: Octreotide. In: Flomenbaum NE, Goldfrank LR, Hoffman RS et al, eds: Goldfrank’s Toxicologic Emergencies. New York NY, 2006;770-773
- ↑ Tran D et al. Oral Hypoglycemic Agent Toxicity Treatment & Management. Jul 14, 2015. http://emedicine.medscape.com/article/1010629-treatment#showall.
- ↑ Fasano CJ et al. Comparison of Octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400-406